Tech Company Inital Public Offerings
CRISPR Therapeutics IPO
CRISPR Therapeutics, operating out of Cambridge, debuted as a public company on 10/18/2016.
Transaction Overview
Company Name
Announced On
10/18/2016
Transaction Type
IPO
Amount
$91,000,000
Proceeds Purpose
We are undertaking this offering in order to access the public capital markets, to increase our liquidity and to support continued development of our research programs. We intend to use the net proceeds of this offering and the concurrent private placement, together with our existing cash and cash equivalents, as follows: approximately $20.0 million to advance the development of our hemoglobinopathy programs; approximately $40.0 million to progress additional pipeline candidates; approximately $10.0 million to further optimize our CRISPR/Cas9 gene editing platform and develop delivery technologies; and the remainder, if any, for manufacturing, working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
610 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
The mission of CRISPR Therapeutics (Nasdaq: CRSP) is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Samarth Kulkarni
President
Rodger Novak
VP - Bus. Development
Lawrence Klein
VP - General Counsel
James Kasinger
VP - Human Resources
Megan Menner
VP - R & D
Tony Ho
Browse more venture capital transactions:
Prev: 10/18/2016: CloudLex venture capital transaction
Next: 10/18/2016: Veritas Genetics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs